PulseCX Welcomes Edward P. Nathan as Chief Creative Officer
Edward P. Nathan, the former Managing Director at Razorfish Health and Chief Creative Officer at Saatchi & Saatchi Healthcare Advertising, recently joined PulseCX, a healthcare marketing agency that specializes in optimizing the customer experience (CX) for pharmaceutical brands, medical devices, and OTC products. Nathan brings extensive experience in primary care and specialty brands, both in the U.S. and globally. His experience spans a vast array of DTC/DTP, professional, and payer communications.
“Ed’s background and skill sets are a perfect fit for PulseCX,” says Jay Bolling, CEO at PulseCX. “He’s a storyteller at heart and truly understands the need for our industry to evolve from feature/benefit selling to customer experience (CX) marketing. Ed will play an important role in achieving our company’s vision of transforming healthcare marketing communications to produce better health outcomes and greater business results.”
Bill McEllen Joins Fingerpaint
Fingerpaint welcomes Bill McEllen, an industry veteran with 20 years experience in client-side sales, marketing and design of creative and effective campaigns. “We are thrilled to have Bill join our team,” says Founder, Ed Mitzen. “With his impressive resume and leadership skills, he will be a vital instrument in Fingerpaint’s continued growth and unwavering ability to produce the highest quality of work for our clients.”
McEllen will focus on global expansion, drive organic, cliental growth and day-to-day activity in Fingerpaint’s New York office. McEllen has been working with McCann since 2003, where he serves as President of both Torre Lazur and Echo Torre Lazur Groups.
Brings former Biogen Co-founder and CEO, Walter Gilbert, PhD to its Board of Directors. Gilbert has co-founded numerous companies including Myriad Genetics, where he is presently Vice Chairman of the Board of Directors. He’s widely recognized for his 40-year academic career in Harvard University which included many discoveries in the fields of molecular biology and genetics.
Kapil Dhingra, MD joins the company’s oncology scientific advisory board. Dr. Dhingra, known as an accomplished medical oncologist and physician-scientist, studied at the All India Institute of Medical Sciences, and held an internal medicine residency at Lincoln Medical Center in New York and a hematology-oncology fellowship at Emory University in Atlanta.
Appoints Gary Zieziula as President and Managing Director, North America of EMD Serono. He brings more than 30 years experience in the pharmaceutical industry, having held senior positions at MSD, Bristol-Myers Squibb, Roche and AMAG Pharmaceuticals. Zieziula originally joined EMD Serono in 2014 as the Chief Commercial Officer. In his new position, he will help grow the biopharma business in North America.
FreshBlood Health Market Consultants
Welcomes neurologist, John Hixson, MD to the company as Senior Medical Director/Neurologist. Dr. Hixson is an author and public speaker and is currently an associate professor at the University of California, San Francisco. He is also a committee member of the American Academy of Neurology.
Appoints Adrian Gilmore as CEO. Gilmore brings more than 20 years of experience in the healthcare and medical device industries. He previously held executive positions at BD, Bayer and CSP Technologies.
Udit Batra joined Merck’s Executive Board. Batra has been with the company since 2011, initially leading the Consumer Health Business. In 2014 he was named CEO and President of Merck Millipore. Also, following the retirement of Bernd Reckmann, Walter Galinat will also be added to the company’s Executive Board. Galiant, who is currently head of the Performance Materials business sector, has been with the company since 1976. In 1996 he took leadership of Eurolab, Merck’s former laboratory distribution division.
Optima Healthcare Solutions
Appoints Aaron Brandwein as Chief Revenue Officer to direct the sales, marketing and services organizations for the company. Brandwein has held numerous executive positions at companies including Homecare Homebase, HealthMEDX and Healthport.
Adds Carlos L. Arteaga, MD to the company’s Medical Advisory Panel. His research specializes in oncogene signaling in breast development/transformation and breast cancer progression, mechanisms of resistance to targeted therapies in breast cancer and novel clinical trials in breast cancer. Currently, Arteaga is Director of the Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center of Vanderbilt University. Anas Younes, MD will also join the panel. He is a medical oncologist with 20 years experience managing patients with lymphoma. He focuses on developing therapies for the treatment of Hodgkin and non-Hodgkin lymphoma. The panel will guide and contribute to the company’s research and development strategies for oncology therapies.
Announces the appointment of Dr. Richard “Mac” McCloskey who now joins the company as Executive Vice President of Clinical Development. His responsibilities entail preparation of trial synopses and protocols, review and approval of case report systems and safety reporting, and drafting clinical trial endpoints, also ensuring that the company meets all regulatory requirements for clinical trial safety and reporting.
Damian A. Braga recently retired from Sanofi Pasteur. Braga started with the company in 1988 as a financial analyst. Because of his determination and hard work, he ascended quickly, becoming CFO in 1996 and President in 2002. As President, the company’s revenue is estimated to have grown by 18% each year. In 2009, under his leadership Sanofi became a contributor in the fight against the Influenza A (H1N1) pandemic.
Welcomes Scott L. Friedman, MD to its Scientific Advisory Board. Dr. Friedman, an expert in fibrosis study is currently a Professor of Medicine, Dean for Therapeutic Discovery and Chief of the division of liver diseases at the Icahn School of Medicine at Mount Sinai Hospital, New York.